Fact based stock research
Astellas Pharma (TSE:4503)


Astellas Pharma stock research in summary

astellas.com


Astellas Pharma shares are less expensive than other comparable stocks. They are safely financed, are good value and show above average growth. We recommend evaluating whether the future of the company Astellas Pharma is really as difficult as the low price of the stock suggests. If you believe that the future of the company is market-typical or even better, then this could be an argument for a share purchase.


Latest Obermatt Ranks


Country Japan
Industry Pharmaceuticals
Index TOPIX 100, Nikkei 225
Size class X-Large

October 4, 2019. Stock data may be delayed. Login to get the most recent research.




Research History: Astellas Pharma

RESEARCH HISTORY 2016 2017 2018 2019
VALUE
VALUE
GROWTH
GROWTH
SAFETY
SAFETY
COMBINED
COMBINED

Last update of Combined Rank: 4-Oct-2019. Financial reporting date used for calculating ranks: 30-Jun-2019. Stock research history is based on the Obermatt Method. The higher the rank, the better Astellas Pharma is in the corresponding investment strategy.


Value Metrics in Detail

VALUE METRICS 2016 2017 2018 2019
PRICE VS. REVENUES (P/S)
PRICE VS. REVENUES (P/S)
PRICE VS. PROFITS (P/E)
PRICE VS. PROFITS (P/E)
PRICE VS. CAPITAL (Market-to-Book)
PRICE VS. CAPITAL (Market-to-Book)
DIVIDEND YIELD
DIVIDEND YIELD
CONSOLIDATED RANK: VALUE
CONSOLIDATED RANK: VALUE

Last update of Value Rank: 4-Oct-2019. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Astellas Pharma; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2016 2017 2018 2019
REVENUE GROWTH
REVENUE GROWTH
PROFIT GROWTH
PROFIT GROWTH
STOCK RETURNS
STOCK RETURNS
CONSOLIDATED RANK: GROWTH
CONSOLIDATED RANK: GROWTH

Last update of Growth Rank: 30-Jun-2019. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Astellas Pharma.


Safety Metrics in Detail

SAFETY METRICS 2016 2017 2018 2019
LEVERAGE
LEVERAGE
REFINANCING
REFINANCING
LIQUIDITY
LIQUIDITY
CONSOLIDATED RANK: SAFETY
CONSOLIDATED RANK: SAFETY

Last update of Safety Rank: 27-Sep-2019. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Astellas Pharma and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Astellas Pharma from October 4, 2019.


We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.

Register for
stock tips now


Stock investing made easy